Explain this page
Arphra AIPlain-English read on Avalo Therapeutics, Inc.’s valuation06-16today
- Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody2d
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates36d
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates36d
- Avalo Therapeutics Announces Pricing of $375 Million Public Offering44d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $47.14 (+220.68%)
Candlestick · 1Y
Open in chart workstation →AVTX
14.60-6.71%H 24.27L 12.52MA50 16.04MA200 —Avg vol 1.0M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.55% | +4.33% | -9.03% | +0.14% | -22.26% | -19.05% | +208.82% | -98.50% | -99.86% | -99.80% | -99.92% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$15.05
Bid
$12.70
150 sh
Ask
$15.97
60 sh
Spread
$3.270
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Technology+2.51%
- Communication Services+1.85%
- Utilities+1.35%
- Consumer Defensive-0.30%
- Industrials-0.32%
- Energy-0.45%
- Basic Materials-0.66%
- Financial Services-0.67%
- Real Estate-0.67%
- Healthcare-1.51%
- Consumer Cyclical-1.74%
Top industries (issuer's industry highlighted)
- Biotechnology-3.87%
- Trucking-5.25%
- Advertising Agencies-5.20%
- Medical - Equipment & Services+5.08%
- Grocery Stores-4.35%
- Computer Hardware-3.67%
- Electronic Gaming & Multimedia+3.56%
- Coal-3.56%
- Communication Equipment-3.51%
- REIT - Diversified-3.43%
- Other Precious Metals-3.35%
- Integrated Freight & Logistics-3.29%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibodyglobenewswire.com·Jun 16, 2026
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updatesglobenewswire.com·May 13, 2026
- Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updatesglobenewswire.com·May 13, 2026
- Avalo Therapeutics Announces Pricing of $375 Million Public Offeringglobenewswire.com·May 05, 2026
- Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrantsglobenewswire.com·May 05, 2026
- Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativaglobenewswire.com·May 05, 2026
Recent analyst activity
DB- Jun 12, 2026GradeBuyBofA Securities Starts Avalo Therapeutics Inc. (AVTX) at BuyBank of America Securities
Peers
No peer list available for AVTX.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|